Hotomi Muneki, Fujihara Keiji, Billal Dewan S, Suzuki Kenji, Nishimura Tadao, Baba Shunkichi, Yamanaka Noboru
Department of Otolaryngology-Head and Neck Surgery, Wakayama Medical University, 811-1 Kimiidera, Wakayama-shi, Wakayama, 641-8509, Japan.
Antimicrob Agents Chemother. 2007 Nov;51(11):3969-76. doi: 10.1128/AAC.00422-07. Epub 2007 Aug 13.
We evaluated the recent prevalence of antimicrobial-resistant Haemophilus influenzae isolated from the upper respiratory tracts (URT) of patients in Japan. Mutations in the ftsI gene, which encodes penicillin binding protein 3 (PBP3), and the clonal dissemination of the resistant strains were also investigated. A total of 264 H. influenzae isolates were collected from patients with URT infections. According to the criteria of the Clinical and Laboratory Standards Institute for the susceptibility of H. influenzae to ampicillin (AMP), the isolates were distributed as follows: 161 (61.0%) susceptible strains (MIC < or = 1 microg/ml), 37 (14.0%) intermediately resistant strains (MIC = 2 microg/ml), and 66 (25.0%) resistant strains (MIC > or = 4 microg/ml). According to PCR-based genotyping, 172 (65.1%) of the isolates had mutations in the ftsI gene and were negative for the beta-lactamase (bla) gene. These 172 isolates were thus defined as genetically beta-lactamase-negative ampicillin-resistant (gBLNAR) strains. The ftsI mutant group included 98 (37.1%) strains with group I/II mutations in the variable mutated region (group I/II gBLNAR) and 74 (28.0%) strains with group III mutations in the highly mutated region (group III gBLNAR). Eighty-seven (33.0%) of the isolates were genetically beta-lactamase-negative ampicillin-susceptible (gBLNAS) strains. The group III gBLNAR strains showed resistance to beta-lactams. Only five strains (1.9%) were positive for a bla gene encoding TEM-type beta-lactamase. The three clusters consisting of 16 strains found among the 61 BLNAR strains (MIC > or = 4 microg/ml and without the bla gene) showed identical or closely related DNA restriction fragment patterns. Those isolates were frequently identified among strains with a MIC to AMP of 16 microg/ml. The current study demonstrates the apparent dissemination and spread of a resistant clone of H. influenzae among medical centers in Japan. The gBLNAR strains show a remarkable prevalence among H. influenzae isolates, with the prevalence increasing with time. This fact should be taken into account when treating URT infections.
我们评估了从日本患者上呼吸道(URT)分离出的耐抗菌药物流感嗜血杆菌的近期流行情况。还研究了编码青霉素结合蛋白3(PBP3)的ftsI基因中的突变以及耐药菌株的克隆传播情况。从URT感染患者中总共收集了264株流感嗜血杆菌分离株。根据临床和实验室标准协会关于流感嗜血杆菌对氨苄西林(AMP)敏感性的标准,分离株分布如下:161株(61.0%)敏感菌株(MIC≤1μg/ml),37株(14.0%)中介耐药菌株(MIC = 2μg/ml),66株(25.0%)耐药菌株(MIC≥4μg/ml)。根据基于PCR的基因分型,172株(65.1%)分离株的ftsI基因有突变,且β-内酰胺酶(bla)基因检测为阴性。因此,这172株分离株被定义为基因β-内酰胺酶阴性氨苄西林耐药(gBLNAR)菌株。ftsI突变组包括98株(37.1%)在可变突变区域有I/II组突变的菌株(I/II组gBLNAR)和74株(28.0%)在高度突变区域有III组突变的菌株(III组gBLNAR)。87株(33.0%)分离株为基因β-内酰胺酶阴性氨苄西林敏感(gBLNAS)菌株。III组gBLNAR菌株对β-内酰胺类药物耐药。仅5株(1.9%)编码TEM型β-内酰胺酶的bla基因检测为阳性。在61株BLNAR菌株(MIC≥4μg/ml且无bla基因)中发现的由16株组成的三个簇显示出相同或密切相关的DNA限制性片段模式。这些分离株在对AMP的MIC为16μg/ml的菌株中经常被鉴定出来。当前研究表明,流感嗜血杆菌耐药克隆在日本各医疗中心有明显的传播和扩散。gBLNAR菌株在流感嗜血杆菌分离株中显示出显著的流行率,且流行率随时间增加。在治疗URT感染时应考虑到这一事实。